Hims & Hers Shares Stage a Friday Rally Amidst Regulatory Headwinds

Despite facing a recent FDA warning letter and significant stock sales by company executives, shares of telemedicine provider Hims & Hers surprised markets with a strong performance last Friday. Investors appear to be focusing on the firm’s robust growth narrative, choosing to look past regulatory scrutiny and insider selling activity. The critical question remains whether this optimism is justified.

Impressive Growth Metrics Contrast with Regulatory Concerns

The underlying optimism is fueled by powerful fundamental results. For the second quarter of 2025, Hims & Hers reported a remarkable 73% surge in revenue, reaching $544.8 million. Furthermore, its subscriber base expanded by 31% to over 2.4 million users. The company’s growth trajectory is set to be bolstered by its planned acquisition of the European digital health platform ZAVA. This strategic move is expected to grant immediate access to key markets including the United Kingdom, Germany, France, and Ireland, with projections indicating the deal will become accretive to earnings by 2026.

However, this aggressive growth is now intersecting with regulatory reality. On September 9th, the U.S. Food and Drug Administration (FDA) issued a stern warning to the company. The agency accused Hims & Hers of making “false or misleading” claims on its website. The central allegation was that the company implied its compounded semaglutid products were equivalent to the FDA-approved blockbuster drugs Ozempic and Wegovy, which is not the case. The market’s initial reaction was one of panic, sending the stock down by 8% upon the news.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Insider Sales Meet Renewed Investor Appetite

Adding to the complex picture is a paradox in trading activity. While the company’s leadership has been offloading substantial equity, retail and institutional investors are showing renewed interest. Notably, Chief Financial Officer Oluyemi Okupe disposed of shares worth more than $8 million in mid-September. This trend was mirrored by CEO Andrew Dudum and other top executives, who also sold significant stakes.

Despite these substantial insider sales, the stock advanced 5.7% this past Friday. This upward movement suggests that some market participants may view the recent sell-off as an overreaction. Although trading volume of 12.2 million shares remained below average, the price action signaled a clear, if tentative, rebound attempt.

Wall Street analysts, however, maintain a cautious stance. The prevailing rating on the stock continues to be “Reduce,” reflecting persistent concerns over high regulatory risks and a rich valuation. The upcoming quarterly earnings reports will be crucial in determining whether the company’s impressive growth can successfully counterbalance these mounting challenges.